Orchard Therapeutics Plc Stock Shares Owned By Insiders
| ORTXDelisted Stock | USD 5.27 0.01 0.19% |
Orchard Therapeutics PLC fundamentals help investors to digest information that contributes to Orchard Therapeutics' financial success or failures. It also enables traders to predict the movement of Orchard Stock. The fundamental analysis module provides a way to measure Orchard Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Orchard Therapeutics stock.
Orchard |
Orchard Therapeutics PLC Company Shares Owned By Insiders Analysis
Orchard Therapeutics' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Orchard Therapeutics Shares Owned By Insiders | 12.20 % |
Most of Orchard Therapeutics' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Orchard Therapeutics PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
CompetitionBased on the latest financial disclosure, 12.2% of Orchard Therapeutics PLC are shares owned by insiders. This is 19.63% lower than that of the Biotechnology sector and 13.96% lower than that of the Health Care industry. The shares owned by insiders for all United States stocks is 20.91% lower than that of the firm.
Orchard Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Orchard Therapeutics' direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Orchard Therapeutics could also be used in its relative valuation, which is a method of valuing Orchard Therapeutics by comparing valuation metrics of similar companies.Orchard Therapeutics is currently under evaluation in shares owned by insiders category among its peers.
Orchard Fundamentals
| Return On Equity | -0.72 | |||
| Return On Asset | -0.29 | |||
| Operating Margin | (3.43) % | |||
| Current Valuation | 302.52 M | |||
| Shares Outstanding | 22.76 M | |||
| Shares Owned By Insiders | 12.20 % | |||
| Shares Owned By Institutions | 87.80 % | |||
| Number Of Shares Shorted | 27.2 K | |||
| Price To Earning | (8.06) X | |||
| Price To Book | 4.74 X | |||
| Price To Sales | 17.41 X | |||
| Revenue | 21.84 M | |||
| Gross Profit | (76.52 M) | |||
| EBITDA | (99.34 M) | |||
| Net Income | (72.92 M) | |||
| Cash And Equivalents | 170.89 M | |||
| Cash Per Share | 1.35 X | |||
| Total Debt | 58.09 M | |||
| Debt To Equity | 0.41 % | |||
| Current Ratio | 4.24 X | |||
| Book Value Per Share | 3.53 X | |||
| Cash Flow From Operations | (93.32 M) | |||
| Short Ratio | 0.29 X | |||
| Earnings Per Share | (4.10) X | |||
| Target Price | 16.0 | |||
| Number Of Employees | 166 | |||
| Beta | 0.55 | |||
| Market Capitalization | 380.11 M | |||
| Total Asset | 218.91 M | |||
| Retained Earnings | (900.88 M) | |||
| Working Capital | 107.58 M | |||
| Current Asset | 300.47 M | |||
| Current Liabilities | 46.52 M | |||
| Z Score | -2.64 | |||
| Net Asset | 218.91 M |
About Orchard Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Orchard Therapeutics PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Orchard Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Orchard Therapeutics PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Orchard Stock
If you are still planning to invest in Orchard Therapeutics PLC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Orchard Therapeutics' history and understand the potential risks before investing.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |